+

TN2009000503A1 - Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation - Google Patents

Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation

Info

Publication number
TN2009000503A1
TN2009000503A1 TNP2009000503A TN2009000503A TN2009000503A1 TN 2009000503 A1 TN2009000503 A1 TN 2009000503A1 TN P2009000503 A TNP2009000503 A TN P2009000503A TN 2009000503 A TN2009000503 A TN 2009000503A TN 2009000503 A1 TN2009000503 A1 TN 2009000503A1
Authority
TN
Tunisia
Prior art keywords
oxazolidinon
carboxamides
thiophene
substituted
methyl
Prior art date
Application number
TNP2009000503A
Other languages
English (en)
Inventor
Swen Allerheiligen
Marcus Bauser
Dirk Heimbach
Stefan Heitmeier
Mark Jean Gnoth
Christoph Gerdes
Degenfeld Georges Von
Susanne Rohrig
Ulrich Rester
Elke Dittrich-Wengenroth
Uwe Saatmann
Tersteegen Adrian 12
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000503(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of TN2009000503A1 publication Critical patent/TN2009000503A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
TNP2009000503A 2007-06-20 2009-11-30 Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation TN2009000503A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028319A DE102007028319A1 (de) 2007-06-20 2007-06-20 Substituierte Oxazolidinone und ihre Verwendung
PCT/EP2008/004562 WO2008155032A1 (fr) 2007-06-20 2008-06-07 (oxazolidinon-5-yl-méthyl)-2-thiophène-carboxamides substitués et leur utilisation dans le domaine de la coagulation sanguine

Publications (1)

Publication Number Publication Date
TN2009000503A1 true TN2009000503A1 (en) 2011-03-31

Family

ID=39731148

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000503A TN2009000503A1 (en) 2007-06-20 2009-11-30 Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation

Country Status (43)

Country Link
US (2) US8383822B2 (fr)
EP (1) EP2170877B1 (fr)
JP (1) JP5537421B2 (fr)
KR (1) KR101535312B1 (fr)
CN (1) CN101821259B (fr)
AR (2) AR066981A1 (fr)
AU (1) AU2008266525B8 (fr)
BR (1) BRPI0813736A2 (fr)
CA (1) CA2692166C (fr)
CL (1) CL2008001691A1 (fr)
CO (1) CO6251281A2 (fr)
CR (1) CR11168A (fr)
CU (1) CU23820A3 (fr)
CY (1) CY1113580T1 (fr)
DE (1) DE102007028319A1 (fr)
DK (1) DK2170877T5 (fr)
DO (1) DOP2009000285A (fr)
EC (1) ECSP099807A (fr)
ES (1) ES2397799T3 (fr)
GT (1) GT200900319A (fr)
HK (1) HK1147991A1 (fr)
HN (1) HN2009003424A (fr)
HR (1) HRP20130072T1 (fr)
IL (1) IL202351A (fr)
JO (1) JO2798B1 (fr)
MA (1) MA31535B1 (fr)
MX (1) MX2009013711A (fr)
MY (1) MY150931A (fr)
NZ (1) NZ581540A (fr)
PA (1) PA8784301A1 (fr)
PE (1) PE20090332A1 (fr)
PL (1) PL2170877T3 (fr)
PT (1) PT2170877E (fr)
RS (1) RS52639B (fr)
RU (1) RU2481345C2 (fr)
SG (1) SG182220A1 (fr)
SI (1) SI2170877T1 (fr)
SV (1) SV2009003435A (fr)
TN (1) TN2009000503A1 (fr)
TW (1) TWI413642B (fr)
UA (1) UA98793C2 (fr)
UY (1) UY31133A1 (fr)
WO (1) WO2008155032A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
US20140050743A1 (en) 2011-01-19 2014-02-20 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途
WO2014183667A1 (fr) * 2013-05-17 2014-11-20 天津药物研究院 Solvate d'acide acétique de dérivé d'oxazolidinone, procédé de préparation dudit solvate, et application associée

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
DE59713007D1 (de) 1996-10-14 2009-06-25 Bayer Healthcare Ag Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
AU6518299A (en) 1998-10-16 2000-05-08 Medical Solutions, Inc. Temperature control system and method for heating and maintaining medical items at desired temperatures
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
SK7572002A3 (en) * 1999-12-21 2002-12-03 Upjohn Co Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
JP2005520782A (ja) * 2001-07-12 2005-07-14 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 向上した水溶解度を有するアミド含有化合物およびアミド含有化合物の水溶解度を向上させる方法
BRPI0212726B8 (pt) 2001-09-21 2021-05-25 Bristol Myers Squibb Co compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos
TW200738672A (en) 2001-12-10 2007-10-16 Bristol Myers Squibb Co Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
KR101215153B1 (ko) 2003-11-12 2012-12-24 다이이찌 산쿄 가부시키가이샤 티아졸 유도체의 제조법
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2005179272A (ja) 2003-12-19 2005-07-07 Yamanouchi Pharmaceut Co Ltd カルボキサミド誘導体のマロン酸塩結晶
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1864984A4 (fr) 2005-03-31 2009-12-30 Mochida Pharm Co Ltd Composé spiro tricyclique comprenant un groupement acyle lié à un atome d'azote de cycle
WO2007008142A1 (fr) 2005-07-08 2007-01-18 Astrazeneca Ab Dérivés de sulfonamides hétérocycliques en tant qu'inhibiteurs du facteur xa
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
SG182220A1 (en) 2012-07-30
PE20090332A1 (es) 2009-04-09
RU2010101307A (ru) 2011-07-27
KR20100021615A (ko) 2010-02-25
WO2008155032A1 (fr) 2008-12-24
UA98793C2 (ru) 2012-06-25
CN101821259B (zh) 2013-10-30
HRP20130072T1 (hr) 2013-02-28
ES2397799T3 (es) 2013-03-11
DE102007028319A1 (de) 2008-12-24
CA2692166C (fr) 2015-01-27
EP2170877B1 (fr) 2012-11-21
UY31133A1 (es) 2009-01-30
CY1113580T1 (el) 2016-06-22
CO6251281A2 (es) 2011-02-21
ECSP099807A (es) 2010-01-29
CU23820A3 (es) 2012-06-21
IL202351A (en) 2015-10-29
AU2008266525B8 (en) 2013-09-19
PL2170877T3 (pl) 2013-03-29
TWI413642B (zh) 2013-11-01
US20100184740A1 (en) 2010-07-22
RU2481345C2 (ru) 2013-05-10
SV2009003435A (es) 2010-08-23
US20140057951A1 (en) 2014-02-27
CL2008001691A1 (es) 2008-12-26
RS52639B (en) 2013-06-28
AR066981A1 (es) 2009-09-23
AU2008266525B2 (en) 2013-09-05
JO2798B1 (en) 2014-03-15
CA2692166A1 (fr) 2008-12-24
NZ581540A (en) 2012-01-12
GT200900319A (es) 2011-11-09
PA8784301A1 (es) 2009-02-09
JP2010530383A (ja) 2010-09-09
SI2170877T1 (sl) 2013-03-29
US8383822B2 (en) 2013-02-26
IL202351A0 (en) 2010-06-30
MX2009013711A (es) 2010-02-01
CU20090216A7 (es) 2011-10-14
HN2009003424A (es) 2012-01-05
BRPI0813736A2 (pt) 2014-12-30
HK1147991A1 (en) 2011-08-26
MA31535B1 (fr) 2010-07-01
KR101535312B1 (ko) 2015-07-09
JP5537421B2 (ja) 2014-07-02
PT2170877E (pt) 2013-01-28
AU2008266525A1 (en) 2008-12-24
EP2170877A1 (fr) 2010-04-07
DK2170877T3 (da) 2013-02-11
CN101821259A (zh) 2010-09-01
CR11168A (es) 2010-06-28
DK2170877T5 (da) 2013-03-04
US8846934B2 (en) 2014-09-30
AR067057A1 (es) 2009-09-30
DOP2009000285A (es) 2010-01-31
MY150931A (en) 2014-03-14
TW200911797A (en) 2009-03-16

Similar Documents

Publication Publication Date Title
WO2008155069A3 (fr) Oxazolidinones substituées et leur utilisation
TN2009000503A1 (en) Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
TN2009000132A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
JO3199B1 (ar) مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها
PH12012501699A1 (en) Bisaryl-bonded aryltriazolones and use thereof
MX2011012505A (es) Piperidinas sustituidas.
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
MX2009013709A (es) (oxazolidinon-5-ilmetil)-2-tiofenocarboxamidas sustituidas y su uso en el campo de la coagulación sanguínea.
DE502007006625D1 (de) 3-cyano-5-thiazaheteroaryl-dihydropyridine und ihrnkungen
MX2011012507A (es) Piperidinas sustituidas.
IL194353A0 (en) Lysobactin amides
UA99638C2 (ru) Оксазолидиноны для лечения и/или профилактики сердечной недостаточности
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide
TW200635920A (en) Pyrazinedicarboxamides and their use
ATE489383T1 (de) Isoindolin-1-on-, isoindolin-3-on- und isoindolin-1,3-dion-derivate und ihre verwendung
ATE487714T1 (de) Imino-oxazolidine und ihre verwendung als antikoagulantien
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载